Industry Payments to Urologists and Urologic Advanced Practice Providers in 2021.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 04 05 2023
revised: 14 06 2023
accepted: 21 06 2023
medline: 13 10 2023
pubmed: 31 7 2023
entrez: 30 7 2023
Statut: ppublish

Résumé

To compare industry payments from drug and medical device companies to urologists and urologic advanced practice providers (APPs) in 2021. We used the 2020 Medicare Data on Provider Practice and Specialty file to identify single-specialty urology practices, defined as those where the majority of physicians were urologists. We then used the Open Payments Program Year 2021 data to summarize the value and number of industry payments to urologists and APPs, including nurse practitioners and physician assistants, in these practices. We calculated the total value and number of payments and median total value and number of payments per provider for urologists and urologic APPs. We identified 4418 urologists and 1099 APPs working in single-specialty urology practices in 2021 (Table 1). Of these, 3646 (87%) urologists received at least one industry payment, totaling $14,755,003 from 116,039 payments, and 954 urologic APPs (87%) received at least one industry payment, including 463 nurse practitioners (85%), totaling $401,283 from 13,035 payments, and 491 physician assistants (89%), totaling $543,429 from 14,626 payments. We observed significantly greater median total value and number of payments per provider for urologists ($620 and 24 payments) compared to urologic APPs ($473 and 21 payments; P < .001 and P = .017, respectively). A similar percentage of urologists and urologic APPs received industry payments in 2021. While urologists received a higher total number and total value of payments in 2021, urologic APPs were a common target of industry marketing payments.

Identifiants

pubmed: 37517679
pii: S0090-4295(23)00653-2
doi: 10.1016/j.urology.2023.06.032
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

121-129

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflict of interest to declare.

Auteurs

Sawyer Reed (S)

Morehouse School of Medicine, Atlanta, GA.

Armaan Singh (A)

Pritzker School of Medicine, University of Chicago, Chicago, IL.

Max J Hyman (MJ)

Center for Health and the Social Sciences, University of Chicago, Chicago, IL.

David O Meltzer (DO)

Center for Health and the Social Sciences, University of Chicago, Chicago, IL.

Anne E Sales (AE)

Sinclair School of Nursing, University of Missouri, Columbia, MO.

Ted A Skolarus (TA)

Section of Urology, Department of Surgery, University of Chicago, Chicago, IL.

Parth K Modi (PK)

Section of Urology, Department of Surgery, University of Chicago, Chicago, IL. Electronic address: farajk@med.umich.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH